305 related articles for article (PubMed ID: 28231007)
1. Molecular Dynamics, Recrystallization Behavior, and Water Solubility of the Amorphous Anticancer Agent Bicalutamide and Its Polyvinylpyrrolidone Mixtures.
Szczurek J; Rams-Baron M; Knapik-Kowalczuk J; Antosik A; Szafraniec J; Jamróz W; Dulski M; Jachowicz R; Paluch M
Mol Pharm; 2017 Apr; 14(4):1071-1081. PubMed ID: 28231007
[TBL] [Abstract][Full Text] [Related]
2. Molecular Factors Governing the Liquid and Glassy States Recrystallization of Celecoxib in Binary Mixtures with Excipients of Different Molecular Weights.
Grzybowska K; Chmiel K; Knapik-Kowalczuk J; Grzybowski A; Jurkiewicz K; Paluch M
Mol Pharm; 2017 Apr; 14(4):1154-1168. PubMed ID: 28241116
[TBL] [Abstract][Full Text] [Related]
3. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
4. Amorphous Sulfadoxine: A Physical Stability and Crystallization Kinetics Study.
Aucamp M; Milne M; Liebenberg W
AAPS PharmSciTech; 2016 Oct; 17(5):1100-9. PubMed ID: 26531745
[TBL] [Abstract][Full Text] [Related]
5. How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions.
Pacult J; Rams-Baron M; Chmiel K; Jurkiewicz K; Antosik A; Szafraniec J; Kurek M; Jachowicz R; Paluch M
Eur J Pharm Sci; 2019 Aug; 136():104947. PubMed ID: 31170526
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical characterization of hot melt extruded bicalutamide-polyvinylpyrrolidone solid dispersions.
Andrews GP; AbuDiak OA; Jones DS
J Pharm Sci; 2010 Mar; 99(3):1322-35. PubMed ID: 19798757
[TBL] [Abstract][Full Text] [Related]
7. Effect of Polymer Chain Length on the Physical Stability of Amorphous Drug-Polymer Blends at Ambient Pressure.
Pacułt J; Rams-Baron M; Chrząszcz B; Jachowicz R; Paluch M
Mol Pharm; 2018 Jul; 15(7):2807-2815. PubMed ID: 29791165
[TBL] [Abstract][Full Text] [Related]
8. Molecular Dynamics and Physical Stability of Ibuprofen in Binary Mixtures with an Acetylated Derivative of Maltose.
Grzybowska K; Grzybowski A; Knapik-Kowalczuk J; Chmiel K; Woyna-Orlewicz K; Szafraniec-Szczęsny J; Antosik-Rogóż A; Jachowicz R; Kowalska-Szojda K; Lodowski P; Paluch M
Mol Pharm; 2020 Aug; 17(8):3087-3105. PubMed ID: 32584584
[TBL] [Abstract][Full Text] [Related]
9. Combining crystalline and polymeric excipients in API solid dispersions - Opportunity or risk?
Veith H; Wiechert F; Luebbert C; Sadowski G
Eur J Pharm Biopharm; 2021 Jan; 158():323-335. PubMed ID: 33296719
[TBL] [Abstract][Full Text] [Related]
10. Physical stability of the amorphous anticholesterol agent (ezetimibe): the role of molecular mobility.
Knapik J; Wojnarowska Z; Grzybowska K; Hawelek L; Sawicki W; Wlodarski K; Markowski J; Paluch M
Mol Pharm; 2014 Nov; 11(11):4280-90. PubMed ID: 25310722
[TBL] [Abstract][Full Text] [Related]
11. Dissolution and Solubility Enhancement of the Highly Lipophilic Drug Phenytoin via Interaction with Poly(N-isopropylacrylamide-co-vinylpyrrolidone) Excipients.
Widanapathirana L; Tale S; Reineke TM
Mol Pharm; 2015 Jul; 12(7):2537-43. PubMed ID: 26046484
[TBL] [Abstract][Full Text] [Related]
12. How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions.
Pacułt J; Rams-Baron M; Chmiel K; Jurkiewicz K; Antosik A; Szafraniec J; Kurek M; Jachowicz R; Paluch M
Eur J Pharm Sci; 2021 Apr; 159():105697. PubMed ID: 33568330
[TBL] [Abstract][Full Text] [Related]
13. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
15. Analytical and Computational Methods for the Determination of Drug-Polymer Solubility and Miscibility.
Thakore SD; Akhtar J; Jain R; Paudel A; Bansal AK
Mol Pharm; 2021 Aug; 18(8):2835-2866. PubMed ID: 34041914
[TBL] [Abstract][Full Text] [Related]
16. Stabilization of low glass transition temperature indomethacin formulations: impact of polymer-type and its concentration.
Chokshi RJ; Shah NH; Sandhu HK; Malick AW; Zia H
J Pharm Sci; 2008 Jun; 97(6):2286-98. PubMed ID: 17879977
[TBL] [Abstract][Full Text] [Related]
17. An improved kinetics approach to describe the physical stability of amorphous solid dispersions.
Yang J; Grey K; Doney J
Int J Pharm; 2010 Jan; 384(1-2):24-31. PubMed ID: 19786081
[TBL] [Abstract][Full Text] [Related]
18. Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form.
Puri V; Dantuluri AK; Bansal AK
J Pharm Sci; 2012 Jan; 101(1):342-53. PubMed ID: 21935949
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical investigations and stability studies of amorphous gliclazide.
Jondhale S; Bhise S; Pore Y
AAPS PharmSciTech; 2012 Jun; 13(2):448-59. PubMed ID: 22382730
[TBL] [Abstract][Full Text] [Related]
20. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
